Thought leadership in isotopes takes a step forward as Calian Ltd. joins the Canadian Nuclear Isotope Council

Toronto – May 1 2024 – Since its inception, the Canadian Nuclear Isotope Council (CNIC) has been focused on establishing itself as the pre-eminent thought leader for Canadian isotopes through the delivery of authentic and genuine content that leverages the expertise, insight, and experience of the sector and its members to educate the public.

Today, with the addition of Calian as the newest member of the CNIC, CNIC is even better positioned to share inspirational, research-driven content that drives change and creates educational value for patients and Canadians alike.

Calian is a proudly Canadian company formed more than 40 years ago in Ottawa. The Calian team has been foundational in helping to shape and deliver critical research projects which have led to the expansion of the Canadian isotope sector.

Specifically, in 2018, Calian completed a feasibility study on behalf of Bruce Power that led to the decision to proceed with the design, fabrication and installation of the Isotope Production System (IPS) to produce lutetium-177 (Lu-177), a therapeutic radioisotope used for the targeted treatment of prostate cancer and neuroendocrine tumors. Calian’s work led to both the creation and expansion of the Bruce Power Irradiation Services business line. This business line not only provides the global market with a supply of life-saving medical isotopes and other irradiated products for decades to come, but it also presents a significant opportunity for Bruce Power to secure additional value for its Owners over the life of its assets.

“At a time of unprecedented global demand for medical isotopes, the CNIC is outlining a bold vision for the future that depends on leveraging Canadian expertise to maximize our progress,” said James Scongack, Chair of the CNIC. “By capitalizing on current research to understand isotope market trends through the work of organizations like Calian, we can make sure that the right supports are in place to allow Canada to become the face of medical innovation and lead the international fight against cancer. The world needs more Canadian research, leadership, and expertise.”

“At Calian, we help the world communicate, innovate, learn and lead safe and healthy lives which is why we are proud to support CNIC and work with customers like Bruce Power to secure the future of nuclear research and advance the medical isotopes industry here in Canada” said Dr. Hani Al Anid, VP of Nuclear.  “We believe collaboration will be key to supplying the world with life-saving treatments so that we can help those that need it most. “

Through knowledge sharing, Calian and the CNIC will work together to offer innovative and thought-provoking insights that ensure that the CNIC and its expert members are considered the go-to source for isotopes in Canada.

To learn more about Calian visit

About the Canadian Nuclear Isotope Council

The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization. The CNIC supports over 85 members from across science, academia, healthcare, and nuclear-sector organizations dedicated to maintaining Canada’s position as a global leader in the production of life-saving isotopes. The CNIC raises awareness and advocates for long-term policies that support health-care innovation and will save countless lives for decades to come.

To learn more about the CNIC, visit and follow us on FacebookTwitter, and LinkedIn.

For more information, please contact:

Melody Greaves
Manager, Strategic Relations
Canadian Nuclear Isotope Council

About Calian

We keep the world moving forward. Calian® helps people communicate, innovate, learn, stay safe and lead healthy lives with confidence. Every day, our employees live our values of customer-centricity, integrity, innovation, respect and teamwork to engineer reliable solutions that solve complex problems. That’s Confidence. Engineered. A stable and growing company for 40 years, we are headquartered in Ottawa with offices and projects spanning North American and international markets. Visit to learn about innovative healthcare, communications, learning and cybersecurity solutions.

Visit to learn about innovative healthcare, communications, learning and cybersecurity solutions. 

Media 613-599-8600 x 2298 

Investor Relations